FIELD: medicine.
SUBSTANCE: present invention relates to genetics, molecular biology and medicine. Method is presented by definition of somatic mutations in the tirozon-kinase domain of BCR / ABL gene, responsible for resistance to therapy with imatinib in chronic myeloid leukemia. Method is carried out using RT-PCR with subsequent hybridization with oligonucleotide biological microchip (biochip). Invention enables to determine 11 somatic mutations: M244V, G250E, Y253H, Y253F, E255K, E255V, T315I, M351T, F359C, F359I, F359V. Diagnosis of mutations allows to establish efficiency with a certain probability and appropriateness of treatment of patients with imatinib.
EFFECT: invention allows to perform analysis in a short time and with little material costs and can be used in medicine.
4 cl, 2 dwg, 2 tbl, 4 ex
Authors
Dates
2017-02-02—Published
2015-12-07—Filed